abs178.txt	background		aromatase	inhibitors	are	the	mainstay	of	therapy	for	patients	withhormone	receptor-positive	breast	cancer	in	both	adjuvant	and	metastatic	settings	their	use	clinical	practice	has	been	challenged	by	significantinter-individual	variability	response	tolerability	hence	purpose	ofthis	paper	is	to	provide	a	succinct	review	literature	on	geneticfactors	contributing	this	design	systematic	search	pubmed	was	conducted	identify	studies	thatinvestigated	association	between	germline	polymorphisms	disposition	toxicities	as	well	thoseevaluating	implications	mutations	esr1	results	genes	coding	phase	i	ii	enzymes(pharmacokinetic	genes)	significantly	modulated	exposure	however	there	paucity	data	linking	interindividual	drugexposure	furthermore	pharmacogenetic	interrogatingrelationship	cyp19a1	(the	target	site	aromataseinhibitors	e	pharmacodynamic	gene)	yielded	conflictingresults	acquired	receptors	have	identified	theunderlying	mechanism	resistance	likely	predictdrug	although	some	implicatedpolymorphisms	with	drug-related	side	effects	putativerole	these	predicting	toxicity	warrants	further	validation	conclusion	genetic	pharmacokinetic	genesappear	influence	inhibitor	and/or	prospective	interventional	needed	understand	theapplication	genomics	personalize	breastcancer
